HomeAMPH • NASDAQ
Amphastar Pharmaceuticals Inc
$40.78
After Hours:
$40.78
(0.00%)0.00
Closed: Apr 15, 4:02:00 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$39.62
Day range
$39.31 - $40.90
Year range
$35.62 - $67.66
Market cap
1.96B USD
Avg Volume
431.78K
P/E ratio
15.71
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
178.10M31.91%
Operating expense
42.16M26.47%
Net income
36.17M6.65%
Net profit margin
20.31-19.15%
Earnings per share
0.8820.55%
EBITDA
66.80M50.95%
Effective tax rate
11.44%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
256.81M46.11%
Total assets
1.51B103.90%
Total liabilities
873.49M309.46%
Total equity
639.42M
Shares outstanding
48.10M
Price to book
2.98
Return on assets
8.83%
Return on capital
10.66%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
36.17M6.65%
Cash from operations
23.86M56.73%
Cash from investing
-103.05M-44,899.56%
Cash from financing
-47.08M-191.32%
Net change in cash
-126.51M-10,938.92%
Free cash flow
15.61M11.18%
About
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Founded
1996
Employees
1,761
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu